A prognostic signature for lung adenocarcinoma by five genes associated with chemotherapy in lung adenocarcinoma
The Clinical Respiratory Journal · 2023
DOI: 10.1111/crj.13723 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Clinical Respiratory Journal, 2023. Verfasst von Xiaofeng Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, The Third Affiliated Hospital of Jiaxing University, Jiaxin…. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Plan Project of Jiaxing (Science and Technology Innovation Research for Livelihood).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Lung adenocarcinoma (LUAD) is one of the most common subtypes of lung cancer. Finding prognostic biomarkers is helpful in stratifying LUAD patients with different prognosis.
Methods
We explored the correlation of LUAD prognosis and genes associated with chemotherapy in LUAD and obtained data of LUAD patients from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Drug sensitivity data were acquired from the Genomics of Drug Sensitivity in Cancer (GDSC) database. Differential and enrichment analyses were used to screen the target genes utilizing limma and “clusterProfiler” packages. Then univariate and LASSO Cox analyses were used to select the prognosis‐related genes. Survival analysis was used to estimate the overall survival (OS) of different groups.
Results
Twenty‐three differentially expressed genes (DEGs) were screened between LUAD samples and healthy samples, and BTK , FGFR2 , PIM2 , CHEK1 , and CDK1 were selected to construct a prognostic signature. The OS of patients in the high‐risk group (risk score higher than 0.69) was worse than that in the low‐risk group (risk score lower than 0.69).
Conclusion
The risk score model constructed by five genes is a potential prognostic biomarker for LUAD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, The Third Affiliated Hospital of Jiaxing University, Jiaxing, China.
- Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou, China.
ORCID-Profile: Chunwei Xu, Youcai Zhu
Förderung
- Science and Technology Plan Project of Jiaxing (Science and Technology Innovation Research for Livelihood)
Zitieren
APA
Li, X., Xu, C., Min, Y., Zhai, Z., & Zhu, Y. (2023). A prognostic signature for lung adenocarcinoma by five genes associated with chemotherapy in lung adenocarcinoma. The Clinical Respiratory Journal. https://doi.org/10.1111/crj.13723
Vancouver
Li X, Xu C, Min Y, Zhai Z, Zhu Y. A prognostic signature for lung adenocarcinoma by five genes associated with chemotherapy in lung adenocarcinoma. The Clinical Respiratory Journal. 2023. doi:10.1111/crj.13723
BibTeX
@article{Li2023,
author = {Li, Xiaofeng and Xu, Chunwei and Min, Yonghua and Zhai, Zhanqiang and Zhu, Youcai},
title = {A prognostic signature for lung adenocarcinoma by five genes associated with chemotherapy in lung adenocarcinoma},
journal = {The Clinical Respiratory Journal},
year = {2023},
doi = {10.1111/crj.13723}
}
EUVIMED